Friday, June 26, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 839 of 1,261

  1. US 8604074

    Pro-neurogenic compounds

    The Board of Regents of the University of Texas System · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  2. US 8604159

    Method for preparing functionalized polymers from polymer alcohols

    Nektar Therapeutics · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  3. US 8604184

    Chemically programmable immunity

    United States of America as represented by the Secretary of the Air Force · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  4. US 8604023

    1,4-benzodiazepinone compounds and their use in treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  5. US 8604064

    Process for the preparation of roflumilast

    TAKEDA GMBH · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  6. US 8603456

    Method of treating hair loss with compositions containing interleukin-1

    United Technologies UT AG · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  7. US 8603468

    Neutralization of HCV

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  8. US 8603808

    Leishmania vaccine using sand fly salivary immunogen

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  9. US 8603462

    Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction

    The United States of America—Department of Veterans Affairs · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  10. US 8603978

    Use of muramyl dipeptide (MDP) for treating inflammation

    The United States of America, as represented by the Secretary, Department of Health and Humand Services · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  11. US 8603543

    Mesocellular oxide foams as hemostatic compositions and methods of use

    The Regents of the University of California · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  12. US 8603819

    Compositions and methods for generating musculoskeletal tissue

    The Regents of the University of California · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  13. US 8604011

    Therapy for treatment of chronic degenerative brain diseases and nervous system injury

    The Regents of the University of California · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  14. US 8598312

    Inhibitors of antigen presentation by MHC class II molecules

    Provid Pharmaceuticals Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  15. US 8598364

    Oligomer-protease inhibitor conjugates

    Nektar Therapeutics · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  16. US 8598361

    Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  17. US 8598322

    Anti CEACAM1 antibodies and methods of using same

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  18. US 8598321

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  19. US 8598170

    Dual-acting oxazole antihypertensive agents

    Theravance, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  20. US 8598203

    Treatment of Crohn's disease with laquinimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  21. US 8598316

    Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies

    The Regents of the University of California · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  22. US 8598154

    Pyridyl-amine fused azadecalin modulators

    Corcept Therapeutics Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  23. US 8598164

    Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  24. US 8598181

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.